Shattuck Labs (NASDAQ:STTK – Get Free Report) and Exicure (NASDAQ:XCUR – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk and profitability.
Profitability
This table compares Shattuck Labs and Exicure’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Shattuck Labs | N/A | -43.57% | -40.90% |
| Exicure | N/A | -237.91% | -61.98% |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Shattuck Labs and Exicure, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Shattuck Labs | 1 | 0 | 10 | 2 | 3.00 |
| Exicure | 1 | 0 | 0 | 0 | 1.00 |
Insider and Institutional Ownership
58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 42.8% of Exicure shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by company insiders. Comparatively, 52.8% of Exicure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Shattuck Labs and Exicure”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Shattuck Labs | $1.00 million | 611.19 | -$48.81 million | ($0.51) | -11.94 |
| Exicure | $500,000.00 | 14.28 | -$4.95 million | ($1.32) | -0.83 |
Exicure has lower revenue, but higher earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Shattuck Labs has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Exicure has a beta of 3.64, meaning that its stock price is 264% more volatile than the S&P 500.
Summary
Shattuck Labs beats Exicure on 10 of the 14 factors compared between the two stocks.
About Shattuck Labs
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
About Exicure
Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Receive News & Ratings for Shattuck Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shattuck Labs and related companies with MarketBeat.com's FREE daily email newsletter.
